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Introduction
Diabetes mellitus is a chronic disease that is growing
in prevalence worldwide, and the burden of this dis-
ease will continue to grow.1 Type 2 diabetes mellitus
is a metabolic disorder that results from complex inter-
actions of multiple factors and is characterized by 
2 major defects in insulin action (insulin resistance) and
a relative insulin deficiency (progressive beta cell failure).
Aggressive glycemic control has been demonstrated
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to decrease the risk of long-term microvascular and
macrovascular complications such as neuropathy, ret-
inopathy and myocardial infarction.2 Therefore, effec-
tive treatment often requires therapy directed at both
abnormalities. There is evidence to show that glycemic
control can be improved by early use of combinations
of agents to simultaneously improve insulin secretion
and reduce insulin resistance.3,4 The most commonly
used combination is that of a sulfonylurea and bi-
guanide, which has been proven to effectively control
glycemia in patients with type 2 diabetes.3–6 In this
context, clinical studies have demonstrated that gly-
buride/metformin combinations led to a significantly
greater reduction in fasting plasma glucose (FPG) and
glycosylated hemoglobin (HbA1c) than monotherapy
or the co-administration of glyburide and metformin
in type 2 diabetes.7–12 In addition, single-tablet com-
bination therapies offered the opportunity for simpli-
fying oral antidiabetic regimens, reducing inconvenience
and improving compliance.13–17 This study was designed
to investigate the efficacy and safety of glyburide/
metformin single-tablet compared to glyburide or met-
formin alone in Chinese patients with type 2 diabetes.
Methods
Study population
This was a randomized, double-blind, 4-arm parallel
clinical trial of patients with type 2 diabetes and inad-
equate glycemic control (HbA1c > 7%) previously. The
study protocol was reviewed and approved by institu-
tional review boards in Taiwan, and patients gave written
informed consent before participation.
The inclusion criteria were: age 30–75 years, type
2 diabetes, body mass index (BMI) 18.5–35 kg/m2,
FPG 140–250 mg/dL and HbA1c 7–12% at the
screening visit and FPG ≥ 140 mg/dL at the second
visit, maintained stable sulfonylurea regimen, with or
without metformin use. Doses of sulfonylurea were at
least equal to or exceeded 1 of the following doses:
glimepiride 4 mg/day, glyburide or glipizide 10 mg/
day, gliclazide 160 mg/day. In the case of concomi-
tant use of metformin, the dose was not more than
1,000 mg/day.
Exclusion criteria included: liver disease, renal dis-
ease, renal impairment, heart failure, current significant
gastrointestinal disorder or other conditions which may
interfere with absorption of the study drugs, history
of drug or alcohol abuse, history of diabetic ketoaci-
dosis, hyperglycemic hyperosmolar non-ketotic coma,
known hypersensitivity to glyburide or metformin,
history of stroke, myocardial infarction, coronary 
revascularization, or arrhythmia that required medical
treatment within the past 6 months, proliferative ret-
inopathy, current infection, had been treated with in-
sulin during the past 6 months, seriously dehydrated,
or took other investigation drug, had undergone an
operation within 4 weeks prior to entering the study or
a history of cancer within 5 years, received concomitant
medication known to affect glucose tolerance, hypo-
glycemic action, or to interfere with the metabolism of
the study drugs during the past 1 month.
Study design
After 1 week of placebo washout period, eligible patients
were randomly assigned into 1 of 4 treatment groups:
glyburide 5 mg b.i.d.; metformin 500 mg b.i.d.; gly-
buride/metformin 2.5mg/500mg b.i.d.; or glyburide/
metformin 5.0 mg/500 mg b.i.d. The doses were 
titrated every 2 weeks to a maximum of 4 tablets per
day if the patient’s FPG still exceeded 140 mg/dL.
The investigational drugs and the matching placebo
were prepared by Orient Europharma (OEP) Co. Ltd.,
Taiwan. For active drug, each tablet contained either
glyburide/metformin 2.5 mg/500 mg or 5.0 mg/
500mg. Euglucon® 5mg (glyburide) was manufactured
by Roche Diagnostics, and Glucophage® 500 mg (met-
formin) was manufactured by LIPHA S.A., France. All
study medications were supplied by OEP, Taiwan. At
the end of week 4, down-titration (t.i.d. to b.i.d. or
double dose b.i.d. to t.i.d.) was permitted. The investi-
gators were allowed to reduce the dose of study med-
ication to the previous level if the patient’s FPG was
< 70 mg/dL. If FPG was between 70 and 100 mg/dL
and the patient experienced 1 episode of hypoglycemia,
the investigator could decide whether to reduce the
medication dose based on the patient’s clinical condi-
tion. All patients were maintained at the dose level of
week 4 until the end of the study at week 16.
Efficacy and safety evaluations
The primary efficacy endpoint was the change in HbA1c
from baseline to week 16. The secondary endpoint was
the change in FPG at week 16. Adverse drug events
were recorded and rated by the study investigators and
included any illness, sign, symptom, or clinically sig-
nificant laboratory test abnormality that appeared or
worsened during the course of the clinical trial. Hypo-
glycemia was defined in 2 ways. Symptomatic hypo-
glycemia was defined by the presence of at least 
1 symptom of hypoglycemia and judged by the investi-
gator to be a possible hypoglycemic event. Laboratory-
confirmed hypoglycemia was defined as a plasma glucose
concentration < 60 mg/dL. Gastrointestinal reactions
were defined as symptoms of gastrointestinal side effects
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(diarrhea, nausea/vomiting, abdominal pain). Serious
adverse events were defined as any adverse experience
occurring at any dose that resulted in death, a life-
threatening adverse experience, inpatient hospitaliza-
tion, congenital anomaly, permanent or severe disabling
or other important medical condition that required
medical or surgical intervention to prevent permanent
impairment/damage.
Statistical methods
All patients who completed the entire treatment period
were included in the final analysis. Patients who took
at least 1 study medication were included in the safety
analysis. All statistical assessments were 2-sided and
evaluated at the 0.05 level of significance. Categorical
variables were analyzed using χ2 test or Fisher’s exact
test. Continuous variables were analyzed using t test,
ANOVA, or the Kruskal–Wallis test. The 0.0125 sig-
nificance level applied when performing the Bonferroni
procedure to compare glyburide/metformin with 
glyburide or metformin alone.
Results
A total of 166 patients with type 2 diabetes mellitus were
screened from 5 medical centers in Taiwan. Sixty-six
of them were unqualified due to fluctuation in fasting
glucose values (n = 36), unstable A1c levels (n = 7) and
patients’ refusal to join the study (n=13). One hundred
patients were randomly assigned into this study with 
a total of 76 patients at the end for final analysis (19
terminated prematurely and 5 violated protocol). The
baseline demographic and diabetes characteristics for
all patients randomized are shown in Table 1. There
were no statistically significant differences in terms 
of gender distribution, BMI, age, weight, height and
history of diabetes mellitus among the 4 treatment
groups (p > 0.05). Also, no significant differences in
terms of systolic blood pressure, diastolic blood pres-
sure, pulse, HbA1c and FPG were observed among the
treatment groups (p > 0.05).
The final doses achieved in each group were gly-
buride 19mg, metformin 1,910mg, glyburide 2.5mg/
metformin 500 mg: 8.4/1,680 mg, glyburide 5.0 mg/
metformin 500mg: 17.2/1,723mg. The mean changes
in body weight from baseline were −0.24 kg, −2.07 kg,
0.71 kg, −0.16 kg in the glyburide, metformin, gly-
buride/metformin 2.5/500 mg and glyburide/met-
formin 5.0/500 mg groups, respectively. This was
statistically significantly different in terms of body weight
among treatment groups (p < 0.001).
FPG concentrations
Figure 1A shows the mean changes in FPG from base-
line. They were −43±11mg/dL in the glyburide group,
−41±13mg/dL in the metformin group, −98±11mg/
dL in the glyburide/metformin 2.5mg/500mg group
and −101 ± 10 mg/dL in the glyburide/metformin
5.0 mg/500 mg group, with only the latter 2 groups
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Table 1. Baseline clinical characteristics of all study subjects*
Glyburide Metformin
Glyburide/metformin
2.5 mg/500 mg 5 mg/500 mg(n = 17) (n = 17)
(n = 21) (n = 21)
Age, yr 63 ± 7 59 ± 9 60 ± 7 57 ± 8
Gender
Male 9 (53) 7 (41) 15 (71) 13 (62)
Female 8 (47) 10 (59) 6 (23) 8 (38)
BMI, kg/m2 25.3 ± 34 25.7 ± 3.2 24.2 ± 3.2 24.2 ± 2.7
Weight, kg 63.7 ± 9.6 65.6 ± 11.4 63.8 ± 9.0 61.3 ± 8.8
Duration of DM, yr 8.6 ± 5.9 6.4 ± 4.8 9.0 ± 5.6 6.6 ± 5.6
Baseline HbA1c, % 8.69 ± 0.94 8.88 ± 1.08 8.71 ± 1.10 8.85 ± 1.21
Baseline FPG, mg/dL 247 ± 46 227 ± 43 246 ± 38 243 ± 50
Diabetes medication used before enrolment
Sulfonylurea 17 (100) 17 (100) 21 (100) 21 (100)
Metformin 14 (82) 15 (88) 14 (67) 15 (71)
*Data are presented as mean ± standard deviation or n (%). BMI = body mass index; DM = diabetes mellitus; HbA1c = glycosylated hemoglobin; FPG = fasting
plasma glucose.
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Figure 1. (A) Changes in fasting plasma glucose (FPG) levels from baseline to end of week 16. (B) Changes in glycosylated hemoglobin
(HbA1c) concentrations from baseline to end of week 16.
reaching significant difference (both p < 0.0125
compared with glyburide and metformin, respectively).
In addition, treatment with glyburide/metformin
2.5 mg/500 mg resulted in a 55 mg/dL reduction
(p = 0.001) in FPG compared to glyburide and a
57 mg/dL lowering in FPG compared to metformin
(p = 0.001). Glyburide/metformin 5.0 mg/500 mg
resulted in a significant lowering of FPG compared to
glyburide or metformin alone (−58 mg/dL, p < 0.001
and −60 mg/dL, p = 0.001).
HbA1c levels
After 16 weeks of therapy (Figure 1B), statistically
significant differences among the 4 treatment groups
were observed (p < 0.001). Patients who took gly-
buride had a significant elevation of HbA1c at the
end of treatment (0.52 ± 0.24%, p = 0018), while treat-
ment with metformin resulted in no significant change
in HbA1c (0.09 ± 0.37%, p = NS). Patients who re-
ceived glyburide/metformin 2.5 mg/500 mg tablet
and glyburide/metformin 5.0 mg/500 mg tablet had
significant decreases in HbA1c compared with gly-
buride and metformin, respectively (both p < 0.0125).
Furthermore, treatment with glyburide/metformin
2.5 mg/500 mg resulted in significantly greater reduc-
tion in HbA1c compared to glyburide or metformin
(−1.77%, p < 0.001 and −1.34%, p = 0.002), and treat-
ment with glyburide/metformin 5.0 mg/500 mg
resulted in significant lowering of HbA1c compared
to glyburide or metformin alone (−1.73, p < 0.001
and −1.30, p = 0.005). Respectively, 19% and 24% of
patients in the glyburide/metformin groups had an
A1c concentration less than 7% relative to 12% in the
metformin monotherapy group and 6% in the gly-
buride monotherapy group (Figure 2). In order to
understand the effect of baseline HbA1c on change in
HbA1C, we divided baseline HbA1c into 3 groups
(≥ 8%, 7.0–7.9%, < 7.0%) (Figure 3). We found that
the higher the baseline HbA1c, the greater the re-
duction in HbA1c that was seen in the glyburide/
metformin groups.
Safety and other effects
Patients who received at least 1 dose of the study drugs
were eligible for the safety analysis. This included all
100 patients enrolled at pretreatment (screening) and
randomly assigned into the 4 treatment groups.
Ninety-eight episodes of adverse events (categorized
by body system and COSTART) were reported from
the screening visit to the end of the study. Four (14.3%)
patients reported adverse events associated with hypo-
glycemia in the glyburide/metformin 2.5 mg/500 mg
group, and 2 (8.3%) patients reported adverse events
associated with gastrointestinal disease among all pa-
tients who took metformin during the entire course
of the study.
There were statistically significant differences in
terms of digestive system and nervous system reactions
among the 4 treatment groups during the treatment
period (Table 2). The highest incidence of digestive sys-
tem side effects was 32.0% in metformin group, and the
lowest was 7.7% in the glyburide/metformin 2.5 mg/
500 mg group (p = 0.021). The highest incidence of
nervous system side effects was 15.4% in patients who
received glyburide/metformin 2.5 mg/500 mg, and
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Figure 2. Baseline and final glycosylated hemoglobin (HbA1c) distribution by HbA1c values < 7%, 7–7.9% and ≥ 8%.
the lowest was 4.0% in patients who took metformin
(p = 0.02).
No death was reported during the study. Of the 4
serious adverse events (due to left hand cutting injury,
right metacarpal bone fracture, hemorrhoid and duo-
denal ulcer, respectively), 1 was reported at the screen-
ing visit and the remainder were experienced by 3
glyburide-treated patients.
With regard to changes in blood pressure, serum
biochemistry and urinary albumin values, there were
no significant differences before and after treatment
among the 4 groups (data not shown).
Discussion
Many patients with type 2 diabetes are unable to
achieve or maintain the American Diabetes Association’s
(ADA) recommended treatment goal of HbA1c levels
below 7%.18 Difficulties in achieving adequate glycemic
control may arise, in part, from the current stepwise
treatment paradigm, which typically begins with
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Table 2. Incidence of common adverse events during the treatment period*†
Body system/COSTART
Glyburide‡ Metformin‡ Glyburide/metformin Glyburide/metformin
p
(n = 23) (n = 25) 2.5/500 mg‡ (n = 26) 5.0/500 mg‡ (n = 26)
Body as a whole 3 (13.04) 1 (4.00) 5 (19.23) 3 (11.54) 0.329
Asthenia 1 (4.35) 0 1 (3.85) 2 (7.69) 0.719
Back pain 2 (8.70) 0 0 0 0.238
Digestive system 3 (13.04) 8 (32.00) 2 (7.69) 7 (26.92) 0.021
Diarrhea 1 (4.35) 2 (8.00) 1 (3.85) 5 (19.23) 0.133
Dry mouth 0 2 (8.00) 0 0 0.158
Gastrointestinal disease 0 2 (8.00) 0 0 0.158
Increased appetite 0 1 (4.00) 0 2 (7.69) 0.286
Metabolic and nutritional 1 (4.35) 1 (4.00) 3 (11.54) 1 (3.85) 0.663
disorders
Musculoskeletal system 2 (8.70) 2 (8.00) 1 (3.85) 1 (3.85) 1.000
Nervous system 0 1 (4.00) 4 (15.38) 0 0.018
Dizziness 0 1 (4.00) 3 (11.54) 0 0.077
Respiratory system 6 (26.09) 6 (24.0) 3 (11.54) 2 (7.69) 0.314
Increased cough 0 2 (8.00) 1 (3.85) 0 0.286
Pharyngitis 3 (13.04) 3 (12.00) 1 (3.85) 1 (3.85) 0.604
Rhinitis 2 (8.70) 1 (4.00) 1 (3.85) 1 (3.85) 1.000
Skin and appendages 1 (4.35) 0 2 (7.69) 2 (7.69) 0.532
Rash 0 0 1 (3.85) 2 (7.69) 0.286
Urogenital system 5 (21.74) 2 (8.00) 1 (3.85) 0 0.115
Urinary tract infection 2 (8.70) 0 0 0 0.238
*Common was defined as when at least 5% of any of the treatment groups had the symptoms; †data are presented as n (%); ‡columns are not additive—number
represents the total number of subjects with at least 1 event.
monotherapy after diet and exercise failure, proceeds
to oral combination therapy and, eventually, to insulin.
The most obvious limitation of this approach is failure
to swiftly address the dual pathophysiologic defects,
insulin resistance and progressive beta-cell dysfunction,
that are present at diagnosis in virtually all patients with
type 2 diabetes. Because it is now appreciated that the
use of a single antihyperglycemic agent corrects only 1
of these defects, initial monotherapy may be less than
optimal for the management of type 2 diabetes. Sul-
fonylureas enhance insulin secretion, whereas met-
formin, among other actions, increases insulin sensitivity,
resulting in reduced hepatic glucose output and in-
creased glucose uptake in muscle, although serious side
effects have been reported.19 The current ADA prac-
tice guidelines recommend early metformin use and
lifestyle changes followed by other oral hypoglycemic
agents and/or insulin regimen in order to aim at A1c
levels less than 7.0%.18 In patients inadequately con-
trolled by diet and exercise alone, initial therapy with
glyburide/metformin tablets provided glycemic control
superior to that of glyburide or metformin monother-
apy.5–9 Therefore, the present study was designed with-
out placebo to examine the efficacy of initial therapy
with traditional glyburide or metformin monotherapy
in patients with more severe hyperglycemia.
Our study found that the single-tablet metformin–
glyburide combinations were more effective than either
component monotherapy in controlling hyperglycemia
in inadequately controlled type 2 diabetes mellitus pa-
tients. Treatment with glyburide/metformin 2.5 mg/
500 mg resulted in significantly greater reduction 
in HbA1c compared to glyburide or metformin alone
(−1.77%, p<0.001 and −1.34%, p=0.002, respectively),
and treatment with glyburide/metformin 5.0 mg/
500 mg resulted in a significant lowering of HbA1c
compared to glyburide or metformin alone (−1.73%,
p < 0.001 and −1.30%, p = 0.005, respectively). Both
combinations also showed statistically significant FPG
reductions compared with glyburide or metformin
monotherapy. Our findings therefore confirmed the
potential of intensified therapy with the single-tablet
metformin–glyburide treatment to improve the con-
trol of hyperglycemia in this population. The mean final
HbA1c achieved in the lower-dose (glyburide/met-
formin 2.5 mg/500 mg) and higher-dose (glyburide/
metformin 5.0 mg/500 mg) combination groups was
similar. The slightly smaller change in HbA1c from
baseline in the higher-dose (glyburide/metformin
5.0 mg/500 mg) combination group, compared with
patients receiving the lower-dose (glyburide/metformin
2.5 mg/500 mg) combination tablet, may be explained
by the slightly higher mean HbA1c at baseline in the
higher-dose patients (8.9% and 8.7% at baseline, re-
spectively). However, the modest changes in HbA1c
in patients randomized to metformin or glyburide
monotherapy in this study are consistent with the results
of previous clinical studies9–11 and showed that com-
bination therapy is a more effective management strat-
egy for type 2 diabetes than trying another monotherapy
when patients are inadequately controlled by oral
antidiabetic monotherapy.14 A recent report indicated
that treatment with glibenclamide–metformin combi-
nation tablets provided better insulin responses to oral
glucose tolerance test in a group of type 2 diabetes
patients, suggesting that combination therapy might
confer more benefits on beta cell function compared
with glibenclamide therapy.20
Although combination therapy was well tolerated,
the duration of this study was too short (16 weeks) to
provide information on long-term safety. While free
combinations of metformin and a sulfonylurea are com-
monly used in clinical practice, the only available pro-
spective long-term evaluation of such a combination
was conducted as a substudy of the UKPDS.2 This was
carried out in 537 patients with hyperglycemia despite
maximal sulfonylurea therapy, who were followed-up
for an average of 6.6 years. The initial publication of
that study revealed an apparent significant (p = 0.039)
excess of diabetes-related mortality in the combination
group compared with patients who received sulfonyl-
urea alone. However, there was no associated increase
in morbidity with the combination, and an analysis of
the much larger overall UKPDS cohort showed that the
apparent increase in mortality in the combination group
arose due to an unexpectedly low mortality in the sul-
fonylurea monotherapy group of the substudy, rather
than excess mortality in the combination group.2 The
single-tablet approach used in the present study dif-
fers importantly from the use of free combinations,
however, as it involved switching from the previously
used either high dose of monotherapy or two combined
therapy to initial therapy with relatively low doses of
metformin and glyburide. As a result, after optimiza-
tion of the dose of each treatment, the superior anti-
hyperglycemic efficacy of the single-tablet combination
treatments was achieved with a lower average exposure
of patients to metformin or glyburide compared with
patients receiving these agents as monotherapy. We did
not measure postprandial glucose levels, which have
become more critical in predicting cardiovascular dis-
ease in individuals with diabetes.21,22 Although the
action of both sulfonylurea and metformin are not
specific to postprandial glucose alterations, the effect
of combination tablets on postprandial glucose control
merits further evaluation.
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Four (14.29%) patients reported adverse events asso-
ciated with hypoglycemia in the glyburide/metformin
2.5 mg/500 mg group. The slightly higher incidence
of hypoglycemia in the combination therapy groups is
consistent with the greater decreases in plasma glucose
observed in these patients. The risk of hypoglycemia
is highly dependent on study design, particularly with
regard to the severity of hypoglycemia at baseline and
the rate of intensification of oral antidiabetic therapy.
However, available data from studies evaluating met-
formin in combination with insulinotropic agents 
in patients who previously received oral antidiabetic
monotherapy suggest that the incidence of hypo-
glycemia with the combinations was relatively similar to
the corresponding incidences with free combinations
of metformin with glibenclamide (18%),3 glimepiride
(22%)15 and repaglinide (33%).16 Furthermore, the
incidence of severe hypoglycemia was low in all of the
treatment arms in our study, and no patient experienced
hypoglycemia categorized as a serious adverse event.
In conclusion, combining glyburide and metformin
in a fixed dose combination tablet may improve adher-
ence by simplifying dosing and reducing the number of
doses and/or tablets included in the patients’ treat-
ment regimens. Improved adherence may contribute
further to improved glycemic control. Therefore, 
glyburide/metformin tablets are safe and effective in
Chinese patients with type 2 diabetes.
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